<DOC>
	<DOC>NCT02518204</DOC>
	<brief_summary>The purpose of this study is to evaluate the concurrent validity between the Brain Performance Test (BPT) subtests and corresponding conventional in-person neuropsychological assessments (NP).</brief_summary>
	<brief_title>Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults</brief_title>
	<detailed_description>This will be a multi-site, randomized, counterbalanced, two-period, two-sequence, validation study of the online, unsupervised Brain Performance Test (BPT). Over the course of 14 days, participants will complete two in-clinic visits during which they will complete both the BPT and in-person neuropsychological assessments (NP).</detailed_description>
	<criteria>Native English speaker Capable and willing to provide informed consent Able to use a computer and mouse without assistance Limited (&lt; 3 days) or no experience with Lumosity.com Limited (&lt; 3 days) or no experience with other cognitive training programs (e.g., FitBrains, CogMed) Willing to refrain from online cognitive training during the course of the study No recent (&lt;1 years) experience with either computerbased or inperson neuropsychological tests (e.g., WAISIV, WISC, HalsteadReitan Battery, MATRICS, CogState, CNS Vital Signs) Good general health assessed via selfreported online physical questionnaire and medical history questionnaire Illiterate or unable to understand written English sufficiently to comprehend study instructions and consent form Uncorrected visual impairment (beyond that required to qualify for a California Driver's License) that may impact the ability to complete assessments (selfreport or determined by the clinician) Uncorrected auditory impairment that may impact the ability to complete assessments (selfreport or determined by the clinician) Selfreported clinical diagnosis for primary psychiatric or neurological disorder (e.g., schizophrenia, multiple sclerosis, attention deficit hyperactivity disorder, Parkinson's disease, epilepsy) Selfreported history of concussion or traumatic brain injury, that is considered clinically significant in the opinion of the investigator (e.g. loss of consciousness â‰¤ 30 minutes) Selfreported diagnosis of mental retardation or pervasive developmental disorder Selfreported diagnosis of Mild Cognitive Impairment, Alzheimer's disease, or other dementia Selfreported history of sustained substance or alcohol abuse or dependence, that is considered clinically significant in the opinion of the investigator (e.g. as defined by DSM5) Selfreport that subject is currently taking an antipsychotic, antidepressant, antianxiety, or a cognitivelyenhancing medication (e.g. Ritalin), or in the last 72 hours, narcotics for pain or other medications that may impact cognitive performance (e.g. sleeping medications/aides or cold/allergy medications) Any other significant medical condition that could impact cognitive performance or result in cognitive impairment in the opinion of the investigator Score &lt;28 on the MMSE Positive urine test for recent substance use on either testing day Breath Alcohol Content of 0.01% or greater on either testing day</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>cognitive assessment</keyword>
	<keyword>neuropsychological assessment</keyword>
	<keyword>Brain Performance Test</keyword>
	<keyword>computerized assessment</keyword>
</DOC>